Australia · Delayed Price · Currency is AUD Healius Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 3.8% to AUD 688.1 million in H1 FY26, with strong cost savings and digital transformation driving margin improvement. FY26 EBIT is expected to align with consensus at around AUD 48 million, with further benefits from cost initiatives and high-value segment growth anticipated.
Fiscal Year 2025
-
The AGM highlighted a strong year with the sale of Lumus Imaging, debt repayment, and a special dividend. Strategic focus remains on digital transformation, operational efficiency, and achieving high single-digit EBIT margins by FY 2027. All resolutions passed with strong shareholder support.
-
Revenue grew 5.7% to AUD 1.34 billion, with pathology up 6% and genomics up 34.7%. Labor costs are targeted to remain flat in FY 2026, with AUD 15–20 million in cost savings planned. High single-digit margins are targeted by June 2027.
-
A simplified, digitally enabled business model is being implemented, targeting high single-digit EBIT margins by June 2027. Key initiatives include the sale of Lumus Imaging, aggressive cost reduction, and expansion of non-MBS revenue streams such as genomics, vet pathology, and clinical trials. Digital transformation and operational standardization underpin efficiency and growth.
-
Group revenue rose 10% year-over-year, driven by strong pathology and Lumus Imaging growth, though higher labor costs weighed on margins. The sale of Lumus Imaging for AUD 965 million will fund debt repayment and a likely special dividend, with further transformation and productivity gains targeted in 2H25.
Fiscal Year 2024
-
The meeting focused on the sale of Lumus Imaging, debt reduction, and a renewed pathology strategy. Shareholders will receive a special dividend post-sale, and the board addressed challenges in margins, government funding, and digital transformation.
-
Group revenue grew 6.1% to AUD 1.74 billion, with EBIT at the top end of guidance and strong segment growth in pathology, imaging, and Agilex. Transformation initiatives exceeded targets, and the Lumus Imaging sale is progressing. Margin and volume improvements continue into FY 2025.